Fox Chase Cancer Center Philadelphia, Pennsylvania
Fox Chase Cancer Center (FCCC) was formed in 1974 by the union of the American Oncologic Hospital, which had been established in 1904, and the Institute for Cancer Research, founded in 1927. Fox Chase became an NCI-designated comprehensive cancer center in 1974.
The mission of FCCC is to prevail over cancer by marshalling hearts and minds in bold scientific discovery, pioneering prevention, and compassionate care. With an overall staff of 2,400, the Center provides both care and conducts research in more than 90 laboratories staffed by 325 physicians and scientists. Clinical, basic, and population research conducted by experts across disciplines in turn enables FCCC to translate new research findings into medical applications that may become models for improved cancer care. FCCC offers the opportunity for participation in clinical trials both at the Center and out in the community, through its Extramural Research Program.
Research programs at the Center encompass Cancer Biology, Cancer Prevention and Control, Immune Cell Development and Host Defense, Developmental Therapeutics, and Women’s Cancer. In addition, FCCC launched a cluster of innovative, team-based research initiatives in 2008, known as the Keystone Programs. These initiatives consist of self-organized groups of scientists, clinicians, and other research professionals seeking to integrate and focus their joined expertise on a significant question in cancer. There are Keystone Programs examining personalized risk and prevention, epigenetics and progenitor cells, blood cell development and cancer, personalized kidney cancer therapy, and head and neck cancer.
FCCC has also created an Institute for Personalized Medicine to conduct treatment based on the genetic makeup of an individual patient’s tumor. This program is expanding understanding of cancer genetics, developing clinical trials of new treatments, and matching emerging drug treatments to the unique genetics of individual patient tumors. The immediate objective of the Institute is to sequence genes known to impact key, targetable, signaling pathways in patients with metastatic disease.
The Research Institute for Cancer Prevention was dedicated in 2010 in the Robert C. Young MD Pavilion for Cancer Prevention Research on the FCCC campus. Among the prevention-related services offered are special programs to help people with family histories or other specific risks of breast and ovarian cancer, gastrointestinal cancer, melanoma, and prostate cancer. The Pavilion includes a Women’s Cancer Center with a broad spectrum of research programs, treatment, and support.
A notable outreach program is the American-Russian Cancer Alliance (ARCA), a consortium of cancer research institutes led by FCCC for the purpose of bridging scientific research and medical education efforts between the two nations.
* This profile was provided by the Fox Chase Cancer Center.